GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Blood, American Society of Hematology, Vol. 123, No. 17 ( 2014-04-24), p. 2745-2747
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Ovid Technologies (Wolters Kluwer Health) ; 2019
    In:  Journal of the American Society of Nephrology Vol. 30, No. 9 ( 2019-9), p. 1573-1586
    In: Journal of the American Society of Nephrology, Ovid Technologies (Wolters Kluwer Health), Vol. 30, No. 9 ( 2019-9), p. 1573-1586
    Abstract: Mechanisms regulating inflammatory response in glomeruli are poorly understood. In this study, the authors identify a novel G protein–coupled receptor (GPCR) that is highly enriched in podocytes, called Gprc5b. Gprc5b is upregulated in common human glomerular diseases, such as IgA nephropathy, lupus nephritis, and diabetic nephropathy. Studies in knockout animals and human podocytes grown in culture show that Gprc5b promotes glomerular inflammation via regulation of NF- κ B pathway in podocytes. Upregulation of Gprc5b in human diseases suggests that this mechanism may play an important role in the pathogenesis of common glomerulopathies. Background Inflammatory processes play an important role in the pathogenesis of glomerulopathies. Finding novel ways to suppress glomerular inflammation may offer a new way to stop disease progression. However, the molecular mechanisms that initiate and drive inflammation in the glomerulus are still poorly understood. Methods We performed large-scale gene expression profiling of glomerulus-associated G protein–coupled receptors (GPCRs) to identify new potential therapeutic targets for glomerulopathies. The expression of Gprc5b in disease was analyzed using quantitative PCR and immunofluorescence, and by analyzing published microarray data sets. In vivo studies were carried out in a podocyte-specific Gprc5b knockout mouse line. Mechanistic studies were performed in cultured human podocytes. Results We identified an orphan GPCR, Gprc5b, as a novel gene highly enriched in podocytes that was significantly upregulated in common human glomerulopathies, including diabetic nephropathy, IgA nephropathy, and lupus nephritis. Similar upregulation of Gprc5b was detected in LPS-induced nephropathy in mice. Studies in podocyte-specific Gprc5b knockout mice showed that Gprc5b was not essential for normal development of the glomerular filtration barrier. However, knockout mice were partially protected from LPS-induced proteinuria and recruitment of inflammatory cells. Mechanistically, RNA sequencing in Gprc5b knockouts mice and experiments in cultured human podocytes showed that Gpr5cb regulated inflammatory response in podocytes via NF- κ B signaling. Conclusions GPRC5b is a novel podocyte-specific receptor that regulates inflammatory response in the glomerulus by modulating the NF- κ B signaling pathway. Upregulation of Gprc5b in human glomerulopathies suggests that it may play a role in their pathogenesis.
    Type of Medium: Online Resource
    ISSN: 1046-6673 , 1533-3450
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2019
    detail.hit.zdb_id: 2029124-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Blood, American Society of Hematology, Vol. 104, No. 11 ( 2004-11-16), p. 1871-1871
    Abstract: Autologous stem cell transplantation as consolidation therapy for de novo AL is able to improve long-term survival especially after second complete remission (CR). In this study, we retrospectively analyzed the karyotyping results performed in 79 out of 101 harvested autologous PBSC from 38 de novo AML patients and 8 de novo ALL in CR. We secondly, analyzed their impact on overall survival (OS) and event-free survival (EFS) post-transplant. All patients had abnormal medullar karyotype at diagnosis. We determined two groups of patients: (1) group 1 with chromosomal abnormalities in harvested PBSC included 10 AML [4 males and 6 females, median age: 53 years (45–66.5)] with at diagnosis 3 favorable, 4 intermediate and 3 unfavorable-risk karyotype ; 2 M0, 3 M2, 1 M3, 2 M4, 2 M5 according to Fab classification ; and 9 autotransplanted patients in CR1 and 1 in CR2 and (2) group 2 without any chromosomal abnormalities in harvested PBSC including 27 AML+ 9 ALL [22 males and 14 females, median age : 44 years (19–70)] ; 1 M0, 1 M1, 4 M2, 5 M3, 11 M4, 5 M5 with at diagnosis 18 favorable prognosis, 1 intermediate and 8 unfavorable-risk karyotype ; among ALL patients, 7 B ALL and 2 T ALL and at transplant, 29 autotransplant in CR1, 6 in CR2 and 1 in CR3]. Cytapheresis products collected contained a median number of 7.7x 108/Kg (5.2–17.3) and 6.79x108/Kg (1.26–16.4) mononuclear cells and 19x106/Kg (3–43) and 20.5x106/Kg (1–4O) CD34+ cells in group 1 and in group 2 respectively. All PBSC harvested were reinfused. Conditionning regimen was quite similar in the two groups and most of the patients of group 1 (60%) and group 2 (70%) received cyclophosphamide and TBI. The hematopoietic reconstitution was similar in the 2 groups [neutrophiles 〉 0.5 G/l: 26 days in group1 versus 19 days in group 2 (p=0,86)]. At 3 years after transplant, there was a trend for a better OS (54.7% CI 95% 40–74.8) (p=0.06) and EFS (52.5% 95%CI 39.6–74) (p=0.05) in patients who received PBSC without any chromosomal abnormalities compared to patients receiving PBSC with abnormal karyotype (OS : 30% 95% CI 11.6–77.3 ; EFS : 30% 95% CI 11.6–77.3). In conclusion, results observed from autologous harvested PBSC karyotyping are promising but a larger number of patients and a longer follow-up could enable to reach a more important significance.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2004
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 108, No. 11 ( 2006-11-16), p. 1876-1876
    Abstract: Introduction: More than half of adults with ALL suffer a relapse. It is generally accepted that the only curative approach at this stage is stem cell transplantation (SCT). In the LALA-94 trial, we analyzed the outcome in patients (pts) undergoing a first relapse, and evaluated the possibility to undergo SCT. Methods: Of 771 ALL pts (15–55 years (y)) who entered the trial and achieved complete remission (CR), 421 experienced a first relapse between 1994 and 2004. Except for 48 pts who died early before any chemotherapy, all other pts were given re-induction therapy with various salvage chemotherapy regimens (355 pts), autologous SCT (3 pts) with cells harvested in first CR, donor lymphocyte infusions (DLI) (1 pt) or allogeneic (allo) SCT (13 pts) from a geno-identical (7 pts) or a pheno-identical (6 pts) donor. After CR achievement with chemotherapy, pts with an HLA-identical sibling or unrelated donor were systematically assigned to allo SCT (61 pts: 33 from a related-identical donor, 27 from MUD, and one from cord blood). When possible, allo SCT was also proposed to pts refractory to re-induction chemotherapy (24 pts: 14 from a related-identical donor, 7 from MUD, and 3 from cord blood). Results: Overall, 187/421 pts (44%) achieved CR. CR proportion according to risk-groups defined in first line therapy were: 52% for standard-risk ALL, 37% for high-risk ALL, 40% for Ph+ ALL, and 36% for CNS+ ALL. There were no significant differences in CR proportion according to the first CR duration. With a median follow-up of 4.3 y, the median overall survival (OS) was 6.3 months (m). Median disease free survival (DFS) was 5.2 m with 5-y DFS at 12%. The estimated 5-y DFS rates were 11%, and 14% for T- and (Ph neg) B-lineage ALL, respectively. SCT (p 〈 0.0001), first CR duration (p=0.03), and platelets at relapse (p=0.02) were predictors of survival in multivariate analysis. 111/421 pts (26%) had a sibling donor identified during first line therapy and available at relapse. 9 more pts had a sibling donor identified at the time of relapse. Overall allo SCT from a sibling donor could be performed in 54 pts (45% of pts with a sibling donor), and 3 pts received DLI. 40 SCT could be performed from a match unrelated donor (MUD) and 4 from cord blood. Our results showed a significantly higher survival rate at 3 y after SCT in second CR as compared to that of SCT at time of relapse (p = 0.02) or to that of SCT with active disease after failure of reinduction chemotherapy (p = 0.005). When comparing allo SCT from MUD and allo SCT from related-identical donor, survival tended to be better with MUD (3-y OS: 31% vs 21%), in relationship with a lower relapse incidence (RI) (3-y RI: 41% vs 64%) while treatment related mortality (TRM) was quiet similar (TRM at 100 days: 19% vs 35%, and 1-y TRM: 37% vs 46%). Conclusions: Our results showed a second CR in less than 50% of pts and difficulties to organize allo SCT in second CR with however a definitive advantage for pts undergoing SCT when compared to chemotherapy alone. This questions about the opportunity to perform allo SCT, when possible, systematically earlier in the evolution of the disease.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2006
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    American Society of Hematology ; 2015
    In:  Blood Vol. 126, No. 23 ( 2015-12-03), p. 976-976
    In: Blood, American Society of Hematology, Vol. 126, No. 23 ( 2015-12-03), p. 976-976
    Abstract: Sickle cell disease (SCD) is a monogenic disorder characterized by severe systemic and vascular inflammation. There is strong evidence that moderate exercise training reduces inflammation in healthy people as well as in multiple diseases conditions. The aim of this study was to characterize the effects of moderate exercise training in a humanized transgenic mouse model of SCD (Townes) in mice expressing exclusively human sickle hemoglobin (SS). The SS mice display many of the features of human SCD including systemic inflammation and chronic anemia. We designed a treadmill training protocol of 1hr/day, 5 days a week for 8 weeks. Prior to the training, the maximal oxygen uptake (V̇O2max) was assessed by an exhaustive incremental exercise. SS mice (n=22) had lower V̇O2max (mean ± SEM: 7,068 ml/kg/hr ± 133 vs. 8,407 ml/kg/hr ± 224.5, p 〈 0.0001) and lower maximal speed (14.3 m/min ± 0.7 vs. 29.3 m/min ± 1.7, p 〈 0.0001) than control AA mice expressing exclusively normal human hemoglobin (n=12). Together these results indicate SS mice have an inherently reduced aerobic exercise capacity; nonetheless, they tolerated a training regimen at 60% of V̇O2max. After eight weeks of training, SS mice had a lower hematocrit (20.3% ± 0.8% vs. 24.4% ± 1.8%, p=0.04; n=8) than untrained SS littermates that were exposed to all other experimental conditions except training. There were only moderate changes in red blood cell count (Trained: 4.8.106/µL ± 0.2, Untrained: 5.7.106/µL ± 0.5, p 〉 0.05) or total hemoglobin (Trained: 5.6 g/dL ± 0.2 vs 6.3 g/dL ± 0.4, p 〉 0.05) between the two groups suggesting the low hematocrit in the trained mice was probably due to increased plasma volume, which is a normal physiological response to exercise training. The spleen/body mass ratio was significantly lower in the trained SS mice compared to the untrained littermates (5.7 mg/g body weight ± 0.3 vs. 7.0 mg/g body weight ± 0.9, p=0.04). Importantly, the spleen was less congested in the trained SS mice, and the magnitude of congestion in all animals (trained and untrained) correlated very strongly with the relative spleen mass (r=0.7, p=0.009). Exercise training significantly increased the percent of oxyhemoglobin in the venous blood of SS mice (Trained: 39% ± 4.3, Untrained: 22.3 ± 4.1, p=0.016). And, there was a corresponding decrease in the percent carboxyhemoglobin (Trained: 2.3% ± 0.7, Untrained 6.2% ± 0.5, p=0.001). These data suggest moderate exercise training may reduce the proportion HbS that is deoxygenated in the venous circulation. In addition, exercise training significantly reduced the peripheral blood white cell count in the SS mice (Training: 14.7.103/µL ± 0.9, Untrained: 21.6.103/µL ± 3.1, p=0.03); this change was reflected by a corresponding lower lymphocyte count in the trained mice (12.103/µL ± 0.8 vs. 17.3.103/µL ± 2.3, p=0.028). Finally, running decreased the liver expression of heme oxygenase-1 (HO-1) mRNA (p=0.04) and the plasma concentration of macrophage inflammatory protein-1β (MIP-1β, p=0.03). Interestingly, HO-1 is implicated in metabolic inflammation and MIP-1β promotes endothelial adhesion of CD8+ T cell through a VCAM-1 dependent pathway. Together with the reductions in leukocyte counts, we suggest that moderate exercise training may reduce sequestration of sickle erythrocytes/congestion, resting blood deoxygenation and inflammation in SCD. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2015
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    BMJ ; 2018
    In:  British Journal of Sports Medicine Vol. 52, No. 4 ( 2018-02), p. 214-218
    In: British Journal of Sports Medicine, BMJ, Vol. 52, No. 4 ( 2018-02), p. 214-218
    Abstract: Sickle cell disease (SCD) is the most common inherited disease in the world. Red blood cell sickling, blood cell-endothelium adhesion, blood rheology abnormalities, intravascular haemolysis, and increased oxidative stress and inflammation contribute to the pathophysiology of SCD. Because acute intense exercise may alter these pathophysiological mechanisms, physical activity is usually contra-indicated in patients with SCD. However, recent studies in sickle-cell trait carriers and in a SCD mice model show that regular physical activity could decrease oxidative stress and inflammation, limit blood rheology alterations and increase nitric oxide metabolism. Therefore, supervised habitual physical activity may benefit patients with SCD. This article reviews the literature on the effects of acute and chronic exercise on the biological responses and clinical outcomes of patients with SCD.
    Type of Medium: Online Resource
    ISSN: 0306-3674 , 1473-0480
    Language: English
    Publisher: BMJ
    Publication Date: 2018
    detail.hit.zdb_id: 2003204-3
    SSG: 31
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Blood Cells, Molecules, and Diseases, Elsevier BV, Vol. 69 ( 2018-03), p. 45-52
    Type of Medium: Online Resource
    ISSN: 1079-9796
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2018
    detail.hit.zdb_id: 1462186-1
    detail.hit.zdb_id: 1237083-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    Ovid Technologies (Wolters Kluwer Health) ; 2015
    In:  Medicine & Science in Sports & Exercise Vol. 47, No. 5S ( 2015-05), p. 875-
    In: Medicine & Science in Sports & Exercise, Ovid Technologies (Wolters Kluwer Health), Vol. 47, No. 5S ( 2015-05), p. 875-
    Type of Medium: Online Resource
    ISSN: 0195-9131
    RVK:
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2015
    detail.hit.zdb_id: 2031167-9
    SSG: 31
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2021
    In:  Nephrology Dialysis Transplantation Vol. 36, No. Supplement_1 ( 2021-05-29)
    In: Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 36, No. Supplement_1 ( 2021-05-29)
    Abstract: Podocyte integrity is crucial for the maintenance of glomerular function in health and disease. Numerous studies have reported that Klotho overexpression, or treatment with recombinant Klotho, reduces glomerular and tubular damage in mouse models of renal disease. However, the mechanism(s) of action are not fully understood. Several recent studies have also reported that Klotho is expressed in podocytes, where it protects against various types of injury. These findings conflict with previous studies, which have shown that renal Klotho expression is exclusively confined to proximal and distal tubular cells. Method To address this discrepancy and enhance our understanding of the putative glomeruloprotective effects mediated by Klotho, we examined the expression pattern of Klotho in human and mouse kidney by several different methods, and explored its protective effects by overexpressing full-length human Klotho directly in podocytes or in a distant organ (i.e. liver). Results Data at the mRNA and protein levels all converged towards an absence or very low expression of Klotho in podocytes. The generation of a podocyte-specific Klotho knockout mouse further demonstrated that its deletion did not affect glomerular structure or function. Moreover, Klotho deficiency did not worsen glomerular injury in an experimental model of glomerulonephritis (anti-GBM). However, when Klotho was overexpressed in hepatocytes (Alb-cre;hKlothofl/+ - Alb-hKL), serum Klotho increased drastically with no changes in Fgf23 or phosphate metabolism. In mice challenged with anti-GBM, renal histology and ultrastructure of the filtration barrier was less severely affected in Alb-hKL compared to WT mice. There were also significantly less albuminuria, podocyte loss and interstitial fibrosis in Alb-hKL mice compared to their WT littermates. In contrast, mice which overexpressed Klotho in podocytes (Pod-hKL) were not protected from renal injury. Conclusion Taken together, these results strongly suggest that Klotho is not expressed in any substantial amounts in human or mouse podocytes, and that membrane-bound Klotho does not play a role in podocyte biology. Importantly, our results confirm a beneficial role for soluble Klotho in protecting podocytes against injury, and in maintaining glomerular integrity and function.
    Type of Medium: Online Resource
    ISSN: 0931-0509 , 1460-2385
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2021
    detail.hit.zdb_id: 1465709-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: British Journal of Haematology, Wiley, Vol. 189, No. 4 ( 2020-05)
    Type of Medium: Online Resource
    ISSN: 0007-1048 , 1365-2141
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 1475751-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...